Report

cancer immunotherapy market

Cancer Immunotherapy Market by Product Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors and Immunomodulators), Application (Lung cancer, Breast cancer, Head and neck cancer, Prostate cancer, Colorectal cancer, Melanoma, and Others), End Users (Hospitals & clinic and Diagnostic centers) and Geography – Global Forecast up to 2026

pages Pages: 89
tables Tables: 97
charts Charts: 67
country Regions/Countries: 4 / 10
compaines Companies: 10
enqhours Enquiry Hours: 10
  • Get Free 10% Customization in this Report

COVID - 19

Covid impact updated reports at special price

Immunotherapy is a treatment that utilizes few parts of a person’s immune system to fight diseases, such as cancer. This can be done either by enhancing one’s immune system to function harder and smarter to fight cancer cells or by providing immune system components, such as human-made immune system proteins.  Cancer immunotherapy fuels the body's natural defenses to struggle against cancer. Immunotherapy is a type of biological therapy. The increasing incidences of cancer day by day, raising awareness about the early diagnosis among cancer patients, efficacy of the therapy compared to other therapies, treatment of cancer amongst the people across the world, and surging geriatric population are some of the primary factors propelling the growth of the global cancer immunotherapy market. Apart from that, the factors that hamper the cancer immunotherapy market are high costs in the treatment and new drugs. The Cancer Immunotherapy Market is projected to grow at the rate of 9.7% CAGR by 2026.

Research Methodology:

The Cancer Immunotherapy Market has been analyzed by utilizing the optimum combination of secondary sources and in-house methodology and a unique balance of primary insights. The real-time valuation of the market is an integral part of our forecasting and market sizing methodology. Industry experts and our primary participants have helped to compile related aspects with accurate parametric estimations for a complete study. The primary participants share is given below:

Cancer Immunotherapy Market

Cancer Immunotherapy Market segmentation by Product Type

  • Monoclonal Antibodies
  • Cancer Vaccines
  • Check Point Inhibitors
  • Immunomodulators

Cancer Immunotherapy Market segmentation by Application

  • Lung cancer
  • Breast cancer
  • Head and neck cancer
  • Prostate cancer
  • Colorectal cancer
  • Melanoma
  • Others

Cancer Immunotherapy Market segmentation by End Users

  • Hospitals & clinic
  • Diagnostic centers

Cancer Immunotherapy Market segmentation by Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

The product type segment of the cancer immunotherapy market is sub-segmented as Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors, and Immunomodulators. Among all product types, the monoclonal segments are having a key share in the market. Rising investments in research and development of monoclonal antibodies since naked antigen-binding antibodies, conjugated monoclonal antibodies, and bispecific antibodies have opened new revenue creation paths for companies that offer oncology therapeutics. These R&D activities lead to the emergence of monoclonal antibodies and owing to various benefits of mAbs they are being examined for various treatments.

If analyzed by the application, the immunotherapy treatment is majorly used to treat lung cancer. The lung cancer segment has the maximum share occupied in the cancer immunotherapy market. This is due to the increasing number of smokers worldwide, a major cause for lung cancer, giving rise to the number of lung cancer cases.

As per the end-user, the cancer immunotherapy market is majorly bifurcated into hospitals & clinics, and diagnostic centers. The hospitals and clinics segment is anticipated to have the fastest growth due to the rising patient pool. Most of the hospitals, specifically in cancer immunotherapy, focus on the treatment of symptomatic conditions. The hospitals and clinics offer cutting-edge treatments which use a patient's immune system to fight cancer. These include cellular therapies, cancer vaccines, and other experimental drugs.

As observed, the North American region is dominating the cancer immunotherapy market due to the rising demand for immunotherapy, increased technological advancements in the treatment of cancer, and the increasing rate of cancer in this region. Thus factors mentioned above are mainly contributing to the market growth.

Immunotherapies in the pipeline are happening to provide more treatment choices and better results than prevailing therapies. The emergence of new drug classes, such as monoclonal antibodies and histone deacetylase (HDAC) inhibitors, designed to target receptors associated with multiple myeloma, is expected to build the market's future. Ongoing studies on similar drugs aim to reduce adverse effects and are anticipated to spur the market's growth.

These are the primary cancer immunotherapy market players -Merck & Co., Inc., Novartis Pharmaceuticals Corporation, F. Hoffmann-La Roche AG, Advaxis Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Pfizer Inc., Bayer AG, Immunomedics Inc., and AstraZeneca plc.

Hence, cancer immunotherapy is observed to be playing a crucial role in cancer treatment. With the considerable pressure of increasing cancer cases and the side effects of other therapies, cancer immunotherapy has exhibited tremendous potential over the past few years.

  • The profiles of key vendors are presented in the report coupled with their latest developments, which gives a better perception of the competition
  • The report also gives a complete perception of the cancer immunotherapy market with the insights such as drivers, opportunities, challenges, trends, and growth of the market.
  • This report also depicts the key factors and challenges encountered by the key vendors and the forthcoming impact of the restraints and opportunities on the key players.
  • Further entails analyzing the past and presenting cancer immunotherapy market size and further penetrating the market worldwide.   
  1. Executive Summary
  2. Industry Outlook
    1. Industry Overview
    2. Industry Trends
  3. Market Snapshot
    1. Market Definition
    2. Market Outlook
      1. Porter Five Forces
    3. Related Markets
  4. Market characteristics
    1. Market Overview
    2. Market Segmentation
    3. Market Dynamics
      1. Drivers
      2. Restraints
      3. Opportunities
    4. DRO - Impact Analysis
  5. Product Type: Market Size & Analysis
    1. Overview
    2. Monoclonal Antibodies
    3. Cancer Vaccines
    4. Check Point Inhibitors
    5. Immunomodulators
  6. Application: Market Size & Analysis
    1. Overview
    2. Lung cancer
    3. Breast cancer
    4. Head and neck cancer
    5. Prostate cancer
    6. Colorectal cancer
    7. Melanoma
    8. Others
  7. End Users: Market Size & Analysis
    1. Overview
    2. Hospitals & clinic
    3. Diagnostic centers
  8. Geography: Market Size & Analysis
    1. Overview
    2. North America
    3. Europe
    4. Asia Pacific
    5. Rest of the World
  9. Competitive Landscape
    1. Competitor Comparison Analysis
    2. Market Developments
      1. Mergers and Acquisitions, Legal, Awards, Partnerships
      2. Product Launches and execution
  10. Vendor Profiles
    1. Merck & Co., Inc.
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    2. Novartis Pharmaceuticals Corporation
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    3. F. Hoffmann-La Roche AG, Advaxis Inc.
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    4. Advaxis Inc.
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    5. Bristol-Myers Squibb Company
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    6. Eli Lilly and Company
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    7. Pfizer Inc.
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    8. Bayer AG
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    9. Immunomedics Inc.
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    10. AstraZeneca plc.
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
  11. Analyst Opinion
  12. Annexure
    1. Report Scope
    2. Market Definitions
    3. Research Methodology
      1. Data Collation and In-house Estimation
      2. Market Triangulation
      3. Forecasting
    4. Report Assumptions
    5. Declarations
    6. Stakeholders
    7. Abbreviations

TABLE 1.           GLOBAL CANCER IMMUNOTHERAPY MARKET VALUE, BY PRODUCT TYPE, 2020-2026 (USD BILLION)

TABLE 2.           GLOBAL CANCER IMMUNOTHERAPY MARKET VALUE FOR MONOCLONAL ANTIBODIES, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 3.           GLOBAL CANCER IMMUNOTHERAPY MARKET VALUE FOR CANCER VACCINES, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 4.           GLOBAL CANCER IMMUNOTHERAPY MARKET VALUE FOR CHECKPOINT INHIBITORS, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 5.           GLOBAL CANCER IMMUNOTHERAPY MARKET VALUE FOR IMMUNOMODULATORS, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 6.           GLOBAL CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 7.           GLOBAL CANCER IMMUNOTHERAPY MARKET VALUE FOR LUNG CANCER, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 8.           GLOBAL CANCER IMMUNOTHERAPY MARKET VALUE FOR BREAST CANCER, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 9.           GLOBAL CANCER IMMUNOTHERAPY MARKET VALUE FOR HEAD AND NECK CANCER, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 10.         GLOBAL CANCER IMMUNOTHERAPY MARKET VALUE FOR PROSTATE CANCER, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 11.         GLOBAL CANCER IMMUNOTHERAPY MARKET VALUE FOR COLORECTAL CANCER, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 12.         GLOBAL CANCER IMMUNOTHERAPY MARKET VALUE FOR MELANOMA, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 13.         GLOBAL CANCER IMMUNOTHERAPY MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 14.         GLOBAL CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2020-2026 (USD BILLION)

TABLE 15.         GLOBAL CANCER IMMUNOTHERAPY MARKET VALUE FOR HOSPITALS & CLINIC, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 16.         GLOBAL CANCER IMMUNOTHERAPY MARKET VALUE FOR DIAGNOSTIC CENTERS, BY GEOGRAPHY, 2020-2026 (USD BILLION)

TABLE 17.         NORTH AMERICA CANCER IMMUNOTHERAPY MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)

TABLE 18.         NORTH AMERICA CANCER IMMUNOTHERAPY MARKET VALUE, BY PRODUCT TYPE, 2020-2026 (USD BILLION)

TABLE 19.         NORTH AMERICA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

TABLE 20.         NORTH AMERICA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2020-2026 (USD BILLION)

TABLE 21.         U.S CANCER IMMUNOTHERAPY MARKET VALUE, BY PRODUCT TYPE, 2020-2026 (USD BILLION)

TABLE 22.         U.S CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

TABLE 23.         U.S CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2020-2026 (USD BILLION)

TABLE 24.         CANADA CANCER IMMUNOTHERAPY MARKET VALUE, BY PRODUCT TYPE, 2020-2026 (USD BILLION)

TABLE 25.         CANADA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

TABLE 26.         CANADA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2020-2026 (USD BILLION)

TABLE 27.         EUROPE CANCER IMMUNOTHERAPY MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)

TABLE 28.         EUROPE CANCER IMMUNOTHERAPY MARKET VALUE, BY PRODUCT TYPE, 2020-2026 (USD BILLION)

TABLE 29.         EUROPE CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

TABLE 30.         EUROPE CANCER IMMUNOTHERAPY MARKET VALUE, END USERS, 2020-2026 (USD BILLION)

TABLE 31.         GERMANY CANCER IMMUNOTHERAPY MARKET VALUE, BY PRODUCT TYPE, 2020-2026 (USD BILLION)

TABLE 32.         GERMANY CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

TABLE 33.         GERMANY CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2020-2026 (USD BILLION)

TABLE 34.         U.K CANCER IMMUNOTHERAPY  MARKET VALUE, BY PRODUCT TYPE, 2020-2026 (USD BILLION)

TABLE 35.         U.K CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

TABLE 36.         U.K CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2020-2026 (USD BILLION)

TABLE 37.         FRANCE CANCER IMMUNOTHERAPY MARKET VALUE, BY PRODUCT TYPE, 2020-2026 (USD BILLION)

TABLE 38.         FRANCE CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

TABLE 39.         FRANCE CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2020-2026 (USD BILLION)

TABLE 40.         ITALY CANCER IMMUNOTHERAPY MARKET VALUE, BY PRODUCT TYPE, 2020-2026 (USD BILLION)

TABLE 41.         ITALY CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

TABLE 42.         ITALY CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2020-2026 (USD BILLION)

TABLE 43.         SPAIN CANCER IMMUNOTHERAPY MARKET VALUE, BY PRODUCT TYPE, 2020-2026 (USD BILLION)

TABLE 44.         SPAIN CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

TABLE 45.         SPAIN CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2020-2026 (USD BILLION)

TABLE 46.         ROE CANCER IMMUNOTHERAPY MARKET VALUE, BY PRODUCT TYPE, 2020-2026 (USD BILLION)

TABLE 47.         ROE CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

TABLE 48.         ROE CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2020-2026 (USD BILLION)

TABLE 49.         ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)

TABLE 50.         ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET VALUE, BY PRODUCT TYPE, 2020-2026 (USD BILLION)

TABLE 51.         ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

TABLE 52.         ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2020-2026 (USD BILLION)

TABLE 53.         CHINA CANCER IMMUNOTHERAPY MARKET VALUE, BY PRODUCT TYPE, 2020-2026 (USD BILLION)

TABLE 54.         CHINA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

TABLE 55.         CHINA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2020-2026 (USD BILLION)

TABLE 56.         INDIA CANCER IMMUNOTHERAPY MARKET VALUE, BY PRODUCT TYPE, 2020-2026 (USD BILLION)

TABLE 57.         INDIA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

TABLE 58.         INDIA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2020-2026 (USD BILLION)

TABLE 59.         JAPAN CANCER IMMUNOTHERAPY MARKET VALUE, BY PRODUCT TYPE, 2020-2026 (USD BILLION)

TABLE 60.         JAPAN CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

TABLE 61.         JAPAN CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2020-2026 (USD BILLION)

TABLE 62.         REST OF APAC CANCER IMMUNOTHERAPY MARKET VALUE, BY PRODUCT TYPE, 2020-2026 (USD BILLION)

TABLE 63.         REST OF APAC CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

TABLE 64.         REST OF APAC CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2020-2026 (USD BILLION)

TABLE 65.         REST OF WORLD CANCER IMMUNOTHERAPY MARKET VALUE, BY PRODUCT TYPE, 2020-2026 (USD BILLION)

TABLE 66.         REST OF WORLD CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2020-2026 (USD BILLION)

TABLE 67.         REST OF WORLD CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2020-2026 (USD BILLION)

TABLE 68.         MERCK & CO., INC: FINANCIALS          

TABLE 69.         MERCK & CO., INC: PRODUCTS & SERVICES    

TABLE 70.         MERCK & CO., INC: RECENT DEVELOPMENTS   

TABLE 71.         NOVARTIS PHARMACEUTICALS CORPORATION: FINANCIALS    

TABLE 72.         NOVARTIS PHARMACEUTICALS CORPORATION: PRODUCTS & SERVICES          

TABLE 73.         NOVARTIS PHARMACEUTICALS CORPORATION: RECENT DEVELOPMENTS        

TABLE 74.         F. HOFFMANN-LA ROCHE AG: FINANCIALS       

TABLE 75.         F. HOFFMANN-LA ROCHE AG: PRODUCTS & SERVICES 

TABLE 76.         F. HOFFMANN-LA ROCHE AG: RECENT DEVELOPMENTS

TABLE 77.         ADVAXIS INC: FINANCIALS      

TABLE 78.         ADVAXIS INC: PRODUCTS & SERVICES

TABLE 79.         ADVAXIS INC: RECENT DEVELOPMENTS           

TABLE 80.         BRISTOL-MYERS SQUIBB COMPANY: FINANCIALS        

TABLE 81.         BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS & SERVICES  

TABLE 82.         BRISTOL-MYERS SQUIBB COMPANY: RECENT DEVELOPMENTS 

TABLE 83.         ELI LILLY AND COMPANY: FINANCIALS 

TABLE 84.         ELI LILLY AND COMPANY: PRODUCTS & SERVICES       

TABLE 85.         ELI LILLY AND COMPANY: RECENT DEVELOPMENTS     

TABLE 86.         PFIZER INC: FINANCIALS         

TABLE 87.         PFIZER INC: PRODUCTS & SERVICES   

TABLE 88.         PFIZER INC: RECENT DEVELOPMENTS  

TABLE 89.         BAYER AG: FINANCIALS           

TABLE 90.         BAYER AG: PRODUCTS & SERVICES     

TABLE 91.         BAYER AG: RECENT DEVELOPMENTS    

TABLE 92.         IMMUNOMEDICS INC: FINANCIALS      

TABLE 93.         IMMUNOMEDICS INC: PRODUCTS & SERVICES

TABLE 94.         IMMUNOMEDICS INC: RECENT DEVELOPMENTS           

TABLE 95.         ASTRAZENECA PLC: FINANCIALS         

TABLE 96.         ASTRAZENECA PLC: PRODUCTS & SERVICES   

TABLE 97.         ASTRAZENECA PLC: RECENT DEVELOPMENTS  

Research Framework

Infoholic Research works on a holistic 360° approach in order to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involves following steps:

  • Data Collation (Primary & Secondary)
  • In-house Estimation (Based on proprietary data bases and Models)
  • Market Triangulation
  • Forecasting
Methodology

Market related information is congregated from both primary and secondary sources.

Primary sources

Involved participants from all global stakeholders such as Solution providers, service providers, Industry associations, thought leaders etc. across levels such as CXOs, VPs and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.

Secondary sources

Include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications along with paid sources such as Factiva, OneSource, Bloomberg among others.

outicon

Cancer Immunotherapy Market by Product Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors and Immunomodulators), Application (Lung cancer, Breast cancer, Head and neck cancer, Prostate cancer, Colorectal cancer, Melanoma, and Others), End Users (Hospitals & clinic and Diagnostic centers) and Geography – Global Forecast up to 2026
Interested in this report?
Get your FREE sample now!

Select User License

$

Want to customize this report?

This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

We offer 10% worth of FREE customization at the time of purchase

Speak to our analyst
Related Reports